Overactive bladder medication: Persistence, drug switching, and reinitiation

2020 ◽  
Vol 39 (8) ◽  
pp. 2527-2534
Author(s):  
Takeshi Soda ◽  
Yu Tashiro ◽  
Shuhei Koike ◽  
Ryosuke Ikeuchi ◽  
Takuya Okada
Keyword(s):  
Overactive Bladder ◽  
Medication Persistence ◽  
Drug Switching

scholarly journals Persistence and adherence of solifenacin treatment for Japanese women with overactive bladder

2012 ◽  
Vol 26 (1) ◽  
pp. 9 ◽  
Author(s):  
Minoru Kobayashi ◽  
Akinori Nukui ◽  
Shinsuke Kurokawa ◽  
Tatsuo Morita
Keyword(s):  
Risk Factors ◽  
Clinical Trials ◽  
Overactive Bladder ◽  
Real World ◽  
Japanese Patients ◽  
Japanese Women ◽  
Adherence Rate ◽  
Medication Persistence ◽  
Related Risk ◽  
Persistence Rate

Persistence and adherence of overactive bladder (OAB) medication have reported to be generally lower in real-world setting as compared with those in clinical trials. However, this information in Japanese population has not been well addressed. Medical records were reviewed for solifenacin as an initial treatment for 172 women with OAB symptom to examine medication persistence, switching, adherence, and the reasons for discontinuation. The associations between persistence and the reasons for discontinuation as well as concomitant conditions regarded as OAB-related risk factors were assessed. The 6-month and 1-year persistence rate of solifenacin were 39.8% and 27.8%, respectively. Consequently, 121 patients (70.3%) discontinued solifenacin, of whom 18 (14.9%) patients switched to other OAB drugs and 9 (7.4%) patients restarted solifenacin. Thus, the adherence rate was 66.8%. More women discontinued solifenacin owing to symptom resolution (41.3%) rather than unfavorable outcomes such as adverse effects (12.4%) and lack of efficacy (21.5%). However, such reason for discontinuation was not the determinant of persistence of solifenacin. There was a non-significant trend towards higher persistence for those with OAB-related risk factors. Japanese women discontinued solofenacin treatment with various reasons in real-world practice, resulting in much lower persistence as compared with clinical trials. A further prospective study in a larger cohort of patients is awaited to better assess their persistence and adherence and understand exact efficacy and tolerability of antimuscarinics for Japanese patients with OAB.

257: The Phosphodiesterase Type 4 Inhibitor, Rolipram, is More Efficient to Relax Detrusor Smooth Muscle in Rats with Overactive Bladder than in Control Rats

2007 ◽  
Vol 177 (4S) ◽  
pp. 86-86
Author(s):  
Stephanie Oger ◽  
Delphine Behr-Roussel ◽  
Katell Mevel ◽  
Jacques Bernabe ◽  
Pierre Denys ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Overactive Bladder ◽  
Detrusor Smooth Muscle ◽  
Phosphodiesterase Type

1678: Experiences Including 5 Year Results of 180 Cases Treated with Low-Dose (100 U) Botulinum-A Toxin Injections into the Detrusor Muscle for Overactive Bladder Refractory to Anticholinergics

2007 ◽  
Vol 177 (4S) ◽  
pp. 556-557 ◽  
Author(s):  
Daniel M. Schmid ◽  
Peter Sauermann ◽  
Matthias Werner ◽  
Daniele Perucchini ◽  
Tullio Sulser ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Low Dose ◽  
Detrusor Muscle ◽  
Botulinum A Toxin

299: The Expressions of Multiple Angiogenic Factors in Bladder Epithelium in Patients with Refractory Overactive Bladder

2005 ◽  
Vol 173 (4S) ◽  
pp. 82-83
Author(s):  
Masahiro Tamaki ◽  
Tadashi Hayashi ◽  
Osamu Ogawa ◽  
Tomohiro Ueda ◽  
Naoki Yoshimura
Keyword(s):  
Overactive Bladder ◽  
Angiogenic Factors ◽  
Bladder Epithelium

11: Results of Overactive Bladder Screening in Over 5000 Midwestern Patients

2006 ◽  
Vol 175 (4S) ◽  
pp. 4-4
Author(s):  
Greeta A. Cherayil ◽  
Nancy K. Bell ◽  
Todd A. Armstrong
Keyword(s):  
Overactive Bladder
Sign in / Sign up

Export Citation Format

Share Document